Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by MineDiggeron Feb 18, 2021 5:58am
208 Views
Post# 32593163

RE:New Corporate Presentation

RE:New Corporate PresentationAs noted y JDavenport in his https://stoxcomm.com/ 2021-02-17 10:57 update the new Corpresentation has some slides deleted and other changes.

To see the changes I suggest uploading the January one and this new Feb one to draftable.com (for those old hands around, it is a pretty visual diff for pdfs and other docs).

In fact I already have and it seems that I can share the link, apparently they have stored the pdfs and will recompare them do demand. [I have ameded the file names slightly, the Feb one has "Reduced Corp see JDavenport" added as I took account of his blog note when I downloaded it]

You will see that there are several deleted slides (draftable can't cope (sync) so well with multiple deletes) and also other edits, but a few additions. Unfortunately page number changes are reported as changes by draftable (well in this free version at least).

Too many changes to list (or even read now actually), but here are a few I noticed...

Slide 4:
004 pain is 2021Q3 vs 2021Q1
Frontal Temp Lobe Dementia (Progranulin?) is 20201Q4 vs 2021Q3


Some deletions:
  • xb3-004 Pain
  • Chiesi slide 12, then through 26, 28-31
  • 001 Path To Market slide 38

Some additions:
  • Peptide discovery
  • LRP1 Receptor slide
  • More comparisons to Transferrin (better)
  • Platform Validation
  • MedImmune collaboration slide
  • Progranulin gets own slides 39..
  • Patents
  • Highlights


Cheers

MD
<< Previous
Bullboard Posts
Next >>